Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma
- Conditions
- Stage IV Skin Melanoma
- Registration Number
- NCT01960634
- Lead Sponsor
- Grupo Español Multidisciplinar de Melanoma
- Brief Summary
This is a multi-centric translational study with biological samples collection. The aim of this study is to validate a method to detect BRAFV600 in blood samples.
Samples: Blood from patients with BRAFV600 metastatic melanoma collected following standard medical practice.
The treatment is not the aim of the study. Patients can be treated either with specific or no-specific drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 58
- Confirmed diagnosis of melanoma and BRAFV600
- Signed Informed Consent Form
- Unresectable phase III or phase IV melanoma
- The patients should be starting a treatment for melanoma (either first line or subsequent lines)
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of patient in which BRAF V600 in blood samples is present/absent two years
- Secondary Outcome Measures
Name Time Method Rate of patients with BRAFV600 present in tumor sample vs blood sample two years
Trial Locations
- Locations (13)
Hospital Infanta Cristina
🇪🇸Madrid, Badajoz, Spain
Hospital Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Hospital Insular de Gran Canaria
🇪🇸Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Costa del SOl
🇪🇸Marbella, Málaga, Spain
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital Universitario Quirón Dexeus
🇪🇸Barcelona, Spain
Hospital Miguel Servet
🇪🇸Zaragoza, Spain
Hospital Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Ramón y Cajal
🇪🇸Madrid, Spain
Hospital Marques de Valdecilla
🇪🇸Santander, Spain
Hospital Virgen de la Salud
🇪🇸Toledo, Spain
Fundación Instituto Valenciano de Oncología
🇪🇸Valencia, Spain